• Successful completion of second safety review of TetraDerm clinical trial's second cohort
• No adverse events observed, confirming safety profile of product
• Third cohort to focus on weight loss patients seeking body contouring procedures

Tetratherix, a developer of novel clinical products based on its patented biomaterial polymer platform technology, has announced the successful completion of the second safety review meeting of the second cohort of the TetraDerm clinical trial. The trial is studying the product's ability to prevent scar formation in surgical incisions. Nine patients in the second cohort have successfully completed their 6-week follow-up assessments, with no procedural or technical adverse events observed or reported. This confirms the differentiated and market-leading safety profile of the TetraDerm product. Based on the clinical observations from the first and second cohorts, the principal investigator, Dr. Drew Cronin, will begin patient enrollment for the third cohort in the first quarter of 2026. The majority of the third cohort will be represented by the fast-growing segment of the plastic and reconstructive surgical market, including patients undergoing body contouring procedures resulting from weight loss following the recent rapid uptake of obesity and weight loss treatments. As the obesity and weight loss medication market continues to expand rapidly, the resulting demand for clinically proven safe and effective body contouring products like TetraDerm is expected to grow exponentially. Tetratherix is now positioned at the epicentre of surgical site management, delivering a high-margin, scalable solution to a multi-billion-dollar problem.

As Tetratherix moves into the third cohort of the TetraDerm clinical trial, the company is positioned to address the profound psychological and physical toll of scarring for patients undergoing surgical procedures. The safety profile proven in the second cohort provides the necessary foundation for TetraDerm to reduce wound tension and optimize the healing environment, ultimately offering a more aesthetic, reliable solution for the complex and large-scale surgeries required in the rapidly growing reconstructive surgical market resulting from weight loss.